Handling Parathormone Receptor Type 1 in Skeletal Diseases: Realities and Expectations of Abaloparatide,Trends in Endocrinology & Metabolism

当前位置： X-MOL 学术 › Trends Endocrin. Met. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Handling Parathormone Receptor Type 1 in Skeletal Diseases: Realities and Expectations of Abaloparatide
Trends in Endocrinology & Metabolism ( IF 11.4 ) Pub Date : 2019-10-01 , DOI: 10.1016/j.tem.2019.07.014
Juan A Ardura ₁ , Sergio Portal-Núñez ₁ , Verónica Alonso ₁ , Beatriz Bravo ₁ , Arancha R Gortazar ₁

Affiliation

Musculoskeletal disorders represent an elevated socioeconomic burden for developed aging societies. Osteoporosis (OP) has been treated with antiresorptive therapies or with teriparatide that was until recently the only anabolic therapy. However, approval of osteoporosis treatment in postmenopausal women with abaloparatide, which is an analog of parathyroid hormone-related peptide (PTHrP), has created a new alternative for OP management. The success of this new treatment is related to differential mechanisms of activation of PTH receptor type 1 (PTH1R) by abaloparatide and PTH. Here, we address the distinguishing mechanisms of PTH1R activation; the effects of PTH1R stimulation in osteoblast, osteocytes, and chondrocytes; the differences between PTH and abaloparatide actions on PTH1R; potential safety concerns; and future perspectives about abaloparatide use in other musculoskeletal disorders.

中文翻译：

在骨骼疾病中处理 1 型甲状旁腺激素受体：Abaloparatide 的现实和期望

对于发达的老龄化社会，肌肉骨骼疾病代表了更高的社会经济负担。骨质疏松症 (OP) 已通过抗吸收疗法或特立帕肽进行治疗，特立帕肽直到最近还是唯一的合成代谢疗法。然而，批准使用 abaloparatide（甲状旁腺激素相关肽（PTHrP）的类似物）治疗绝经后妇女骨质疏松症，为 OP 管理创造了新的替代方案。这种新疗法的成功与 abaloparatide 和 PTH 激活 PTH 受体 1 型 (PTH1R) 的不同机制有关。在这里，我们解决了 PTH1R 激活的区别机制；PTH1R 刺激对成骨细胞、骨细胞和软骨细胞的影响；PTH和abaloparatide对PTH1R作用的差异；潜在的安全问题；

更新日期：2019-10-01

点击分享查看原文

点击收藏

阅读更多本刊最新论文